These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 7967892)

  • 21. [Drug surveillance as seen by the general practitioner. Apropos of a survey of 4175 physicians].
    Begaud B; Haramburu F; Péré JC; Delmas N; Lorson B; Albin H
    Therapie; 1984; 39(5):453-7. PubMed ID: 6506000
    [No Abstract]   [Full Text] [Related]  

  • 22. Communicating the risks and benefits of medicines.
    Schmid EF; Smith DA; Ryder SW
    Drug Discov Today; 2007 May; 12(9-10):355-64. PubMed ID: 17467571
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The drug safety review process.
    Somberg J
    Am J Ther; 2007; 14(2):119. PubMed ID: 17414577
    [No Abstract]   [Full Text] [Related]  

  • 24. Strategy for surveillance of adverse drug events.
    Bright RA
    Food Drug Law J; 2007; 62(3):605-16. PubMed ID: 17915403
    [No Abstract]   [Full Text] [Related]  

  • 25. [More transparency in drug safety].
    Saussele T
    Med Monatsschr Pharm; 2009 Sep; 32(9):325. PubMed ID: 19795694
    [No Abstract]   [Full Text] [Related]  

  • 26. [Chemical surveillance in the industrial environment].
    Conso F
    Rev Prat; 1987 Apr; 37(23):1321-5. PubMed ID: 3602879
    [No Abstract]   [Full Text] [Related]  

  • 27. Pharmacovigilance in India: how safe are the new drugs? How sure are we?
    Joshi SR; Sapatnekar SM
    J Assoc Physicians India; 2008 Dec; 56():933-4. PubMed ID: 19322970
    [No Abstract]   [Full Text] [Related]  

  • 28. Scientific challenges in postmarketing surveillance of ocular adverse drug reactions.
    Fraunfelder FW; Fraunfelder FT
    Am J Ophthalmol; 2007 Jan; 143(1):145-149. PubMed ID: 17188050
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Advantages of a microcomputer system in researching duplicated reports].
    Biour M; Wagniart F; Jablonka J; Hamel JD; Weissenburger J; Cheymol G
    Therapie; 1986; 41(5):383-4. PubMed ID: 3810530
    [No Abstract]   [Full Text] [Related]  

  • 30. [Surveillance studies criticized. A marketing effort for expensive drugs? "Not throwing the baby out with the bath water" (interview by Dr. Beate Schumacher)].
    Selbmann HK
    MMW Fortschr Med; 2009 Aug; 151(34-35):6. PubMed ID: 19771776
    [No Abstract]   [Full Text] [Related]  

  • 31. An adverse drug reaction reporting program.
    Wasan SM; Marshall LB
    Can J Hosp Pharm; 1989 Dec; 42(6):239-41. PubMed ID: 10318356
    [No Abstract]   [Full Text] [Related]  

  • 32. [Regulatory guidelines and drug safety].
    Flury W
    Ther Umsch; 1993 Jan; 50(1):49-51. PubMed ID: 8378867
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Should new drugs be avoided?
    Child Health Alert; 2002 Jun; 20():2. PubMed ID: 12096722
    [No Abstract]   [Full Text] [Related]  

  • 34. [Misuse of drugs: conclusions of the pharmacovigilance workshops at La Baule, France].
    Fermont I;
    Therapie; 2002; 57(3):283-8. PubMed ID: 12422543
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prescription for trouble: common drugs, hidden dangers. Tens of people are at risk.
    Consum Rep; 2006 Jan; 71(1):34-9. PubMed ID: 16491527
    [No Abstract]   [Full Text] [Related]  

  • 36. Post marketing surveillance. Traps for the unwary.
    Marley J; Mant A
    Aust Fam Physician; 1993 Jun; 22(6):1009-11, 1013. PubMed ID: 8338446
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Research methods in drug surveillance.
    Engel RR; Grohmann R; Rüther E; Hippius H
    Pharmacopsychiatry; 2004 Mar; 37 Suppl 1():S12-5. PubMed ID: 15052510
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmaceutical postmarket review: fact or fiction?
    Schanz SJ
    Food Drug Law J; 2007; 62(3):493-500. PubMed ID: 17915391
    [No Abstract]   [Full Text] [Related]  

  • 39. [Drug news].
    Autret-Leca E
    Arch Pediatr; 2008 Aug; 15(8):1349-55. PubMed ID: 18585013
    [No Abstract]   [Full Text] [Related]  

  • 40. FDA attempting to overcome major roadblocks in monitoring drug safety.
    Zielinski SL
    J Natl Cancer Inst; 2005 Jun; 97(12):872-3. PubMed ID: 15956645
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.